A-412,997 is a drug which acts as a dopamine agonist that is used in scientific research. It is the first drug developed that is a highly selective agonist for the D4 subtype, with significantly improved selectivity over older D4-preferring compounds such as PD-168,077 and CP-226,269.[1] In animal tests it improved cognitive performance in rats to a similar extent as methylphenidate, but without producing place preference or other signs of abuse liability.[2][3] Also unlike other dopamine agonists, selective D4 agonists do not cause side effects such as sedation and nausea, and so might have advantages over older dopamine agonist drugs.[4]
References
^Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD (September 2005). "A-412997 is a selective dopamine D4 receptor agonist in rats". Pharmacology Biochemistry and Behavior. 82 (1): 140–7. doi:10.1016/j.pbb.2005.08.001. PMID16153699. S2CID10270715.
^Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, et al. (September 2005). "A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats". Pharmacology Biochemistry and Behavior. 82 (1): 148–55. doi:10.1016/j.pbb.2005.08.002. PMID16154186. S2CID31796938.
^Woolley ML, Waters KA, Reavill C, Bull S, Lacroix LP, Martyn AJ, et al. (December 2008). "Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat". Behavioural Pharmacology. 19 (8): 765–76. doi:10.1097/FBP.0b013e32831c3b06. PMID19020411. S2CID36272297.
^Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, et al. (May 2005). "Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets". Pharmacology Biochemistry and Behavior. 81 (1): 211–9. doi:10.1016/j.pbb.2005.03.012. PMID15894081. S2CID46690866.